Tag: financial

Press release
25 June 2026 - N° 14

Generated Record Operating Cash Flow of $54.1 Million; Maintained Profitability 

NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4^th floor, 75013 Paris, France.

NEW YORK, 25 juin 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique qui utilise sa technologie pionnière d’édition du génome pour développer des thérapies cellulaires et géniques, a tenu son assemblée générale mixte ce jour à 14h30, heure de Paris, à l’auditorium du site Biopark, situé au 11 rue Watt, 4^ème étage, 75013 Paris, France.

Bridging the Gap Between Making Money and Actually Building Wealth

Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community

LITTLE ROCK, Ark., June 25, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that it will report its second quarter 2026 financial results prior to the opening of trading on the Nasdaq Stock Exchange on July 30, 2026. A conference call to discuss those earnings will be held the same day at 8:30 AM Eastern Time.

LEXINGTON, Mass. and AMSTERDAM, June 25, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the closing of its previously announced underwritten public offering of 5,686,813 ordinary shares at a public offering price of $45.50 per share, which includes 741,758 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, were approximately $259 million. All securities in the offering were sold by uniQure.